August 2, 2016
The Japanese ethical drug market expanded 2.5% year on year to 2.6 trillion yen in April-June despite the April biennial price revision, driven by novel hepatitis C drugs and the immuno-oncology drug Opdivo (nivolumab), according to data released by IMS...read more